Cardio Diagnostics Hldgsの空売り状況は、投資家がCardio Diagnostics Hldgsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Cardio Diagnostics Hldgs (NASDAQ:CDIO) 株価情報, 空売り情報

Cardio Diagnostics Hldgs

Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Holdings Inc

Cardio Diagnostics Holdings Inc. - Warrant

Earnings

Earnings Beats

Earnings Misses

News

LSTR

Landstar System Q1 EPS $0.85 Misses $0.99 Estimate, Sales $1.15B Beat $1.13B Estimate

WIIM

SGMO

Sangamo Therapeutics shares are trading lower after the company reported worse-than-expected Q1 financial results.

Bridgemarq Real Estate (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BRE#TSX">BRE</a>) reported quarterly earnings of $0.20 per share. This is a 5.26 percent increase over earnings of $0.19 per share from the same period last year. The company reported $77.97 million in sales this quarter. This is a 562.62 percent increase over sales of $11.77 million the same period last year.

TSX:BRE

Bridgemarq Real Estate Q1 Adj. EPS $0.20 Up From $0.19 YoY, Sales $77.97M Up From $11.77M YoY

ITOS

Trading Halt: Halted at 7:50:00 a.m. ET - Trading Halt: Halt News Pending

Palmer Luckey, the virtual-reality prodigy who sold Oculus to Facebook for $2 billion in 2014, says that payday granted him entry to an ultra-exclusive group chat called the "B Boys Club."
What Happened: The only password to the group chat is a unicorn-level exit: founders must have sold a company for at least $1 billion. "It's all boys who have sold a company for at least $1 billion," Luckey <a href="https://www.youtube.com/watch?v=21I_3VEs0iI">told</a> Peter Diamandis on the "Moonshots" podcast. While he insists women aren't barred, none are in the thread.
That omission is striking given deals like L'Oréal's $1.2 billion purchase of IT Cosmetics from co-founder Jamie Kern Lima in 2016.
By club standards, Instagram's Kevin Systrom and Mike Krieger (<a href="https://www.benzinga.com/news/15/10/5891968/instagrams-fifth-anniversary-how-good-of-a-deal-was-this-for-facebook">sold</a> to Facebook for $1 billion in 2012) would qualify easily. So would WhatsApp's Jan Koum and Brian Acton, who <a href="https://www.benzinga.com/news/14/02/4322191/update-facebook-announces-16b-cash-stock-merger-with-whatsapp">fetched</a> $19 billion two years later. Slack co-founder Stewart Butterfield dwarfs them all, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/20/12/18616683/6-salesforce-analysts-react-to-slack-deal-game-changer-potential">exiting</a> to Salesforce for $27.7 billion in 2021.
See also: <a href="https://www.benzinga.com/25/05/45370909/china-rejects-us-blame-for-fentanyl-crisis-calls-tariff-penalties-unreasonable-amid-easing-trade-tensions">China Rejects US Blame For Fentanyl Crisis, Calls Tariff Penalties Unreasonable Amid Easing Trade Tensions</a>
Some of the planet's richest men, however, are stuck on read. Meta chief Mark Zuckerberg, who&#8217;s worth roughly $226 billion by Bloomberg's latest count, never actually sold Facebook, so he's out, as are Bill Gates, Sam Altman and Warren Buffett.
What To Know: Luckey, now <a href="https://www.forbes.com/profile/palmer-luckey/">valued</a> by Forbes at about $2.5 billion thanks to defense-tech startup Anduril, spends his chat time "shaming" peers into using their fortunes for more than vintage race cars.
"Guys, you have so much money. Why are you not doing what you know is the right thing to do with this capital?" he recalled messaging.
Luckey believes founders should personally build the world they envision instead of outsourcing philanthropy. Some converts are redirecting cash; others, he concedes, still prefer the fast lane. "I'm not saying everyone should become a vigilante crime fighter, but why wouldn't you use your resources to do the thing that you know needs to be done?" Luckey said.
Image via Just dance/Shutterstock
Read next: <a href="https://www.benzinga.com/news/global/25/05/45369837/piers-morgan-tears-into-pakistani-expert-who-says-isi-didnt-know-osama-bin-laden-was-living-near-military-base-all-they-had-to-do-was-get-a-pair-of-binoculars">Piers Morgan Tears Into Pakistani Expert Who Says ISI &#8216;Didn&#8217;t Know&#8217; Osama Bin Laden Was Living Near Military Base: &#8216;All They Had To Do Was Get A Pair Of Binoculars&#8217;</a>

Tech

Oculus Founder Palmer Luckey Reveals He's In An Invite-Only Group Chat With Just One Entry Rule

Kohl's intends to use the net proceeds from the sale of the Notes in a series of transactions resulting in the repayment of borrowings under its revolving credit facility. Kohl's expects to borrow under its revolving credit facility to repay all of its 4.25% notes due 2025 at maturity.

Kohl's Plans $360M Senior Secured Notes Offering Due 2030, Cites Use Of Proceeds For Debt Repayment Strategy

Telsey Advisory Group analyst Dana Telsey maintains FIGS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIGS#NYSE">FIGS</a>) with a Market Perform and maintains $5 price target.

Price Target

Analyst Ratings

FIGS

Telsey Advisory Group Maintains Market Perform on FIGS, Maintains $5 Price Target

Nayax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYAX#NASDAQ">NYAX</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.04 by 380 percent. This is a 230.61 percent increase over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $81.11 million which missed the analyst consensus estimate of $85.59 million by 5.23 percent. This is a 26.81 percent increase over sales of $63.96 million the same period last year.

NYAX

Nayax Q1 EPS $0.19 Beats $0.04 Estimate, Sales $81.11M Miss $85.59M Estimate

LSEA

Landsea Homes shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results. Also the company announced it entered into a definitive agreement to be acquired by New Home.

PLRZ

Polyrizon Launches Preclinical Studies For Intranasal Benzodiazepines Targeting $3.15B Acute Seizure Market

CNSP

CNS Pharmaceuticals shares are trading higher after the company announced the transfer from Cortice Biosciences of Orphan Drug Designation for TPI 287.

Chardan Capital analyst Rudy Li maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and maintains $55 price target.

XENE

Chardan Capital Maintains Buy on Xenon Pharmaceuticals, Maintains $55 Price Target

Needham analyst Chris Pierce reiterates Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) with a Buy and maintains $13 price target.

Reiteration

ACHR

Needham Reiterates Buy on Archer Aviation, Maintains $13 Price Target

ARWR

Arrowhead Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.

"We are excited about the opportunites we're seeing across our business and look forward to driving further revenue growth and value for our shareholders in 2025. We continue to expect full year 2025 GAAP EPS to exceed $2.40 per diluted share, and full year 2025 non-GAAP adjusted EPS to exceed $2.80 per diluted share," Mr. Suzuki concluded.

Guidance

BKTI

CORRECTION: BK Technologies Affirm FY25 GAAP EPS Outlook Of More Than $2.40

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) with a Buy and lowers the price target from $50 to $45.

NGNE

HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $45

MVST

Microvast Holdings shares are trading higher after the company reported better-than-expected Q1 sales results.

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and maintains $60 price target.

Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target

EXOD

Exodus Movement shares are trading lower after the company reported worse-than-expected Q1 sales results.

GigaCloud Technology shares are trading higher after the company reported better-than-expected Q1 financial results.

Press Releases

Cardio Diagnostics Holdings Inc. Launches CDIO.AI, A Redesigned Website Enhancing User Experience and Highlighting Our AI-Driven Cardiovascular Solutions

Potential Catalyst Right Around The Corner? CMS To Announce Preliminary Medicare Payment For Cardio Diagnostics' Heart Disease Tests

Cardio Diagnostics Holdings, Inc. Receives Preliminary Medicare Pricing from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests

Cardio Diagnostics Holdings, Inc. to Sponsor and Showcase AI-Powered Solutions at the FLAACOs Annual Conference

Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests

Trump's "Stargate AI" Healthcare/Medical Watch: CSDX, IPA, MGX, CDIO

Global Drug Screening Market Is Forecasted to Reach $19.5 Billion By 2029

Cardio Diagnostics Expands the Reach of its AI-Driven Precision Cardiovascular Medicine Tests by Partnering with Seven New Provider Organizations

Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD™, Actionable Clinical Intelligence™ and New Clinical Advancements at the American College of Cardiology's 74th Annual Scientific Session

Cardio Diagnostics Holdings, Inc. Announces 1-for-30 Reverse Stock Split

BIAF

CDIO

CSDX

INBS

SOBR

TRIB

Abeona Therapeutics

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Amarin Corporation plc - American Depositary Shares

Amarin Corp

Astria Therapeutics

Aura Biosciences

Candel Therapeutics

Cidara Therapeutics

Design Therapeutics

Foghorn Therapeutics

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Genfit

Gossamer Bio

Immutep Limited - American Depositary Shares

Immutep

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

ITeos Therapeutics

Kodiak Sciences

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Monopar Therapeutics

Neurogene

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Solid Biosciences

2seventy bio

Tevogen Bio Holdings

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

Benchmark

Northland Capital Markets

Screenshot 2024-09-16 at 6.26.11 PM

Biotech

General

Potential Catalyst Right Around The Corner? CMS To Announce Preliminary Medicare Payment For Cardio Diagnostics&#39; Heart Disease Tests

Screenshot 2024-05-23 at 10.15.30 PM

Interview

This Medtech Company Is Bringing &#34;Precision&#34; Medicine To Cardiovascular Diagnostics

Screenshot 2024-05-06 at 5.31.30 PM

New Study Shows Cardio Diagnostics&#39; (NASDAQ: CDIO) PrecisionCHD Test Could Save Health Insurers Over $113 Million Annually

Screenshot 2024-04-30 at 5.36.02 PM

Health Care

MRNA

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Screenshot 2024-04-23 at 6.35.19 PM

As the Use of AI In Healthcare Grows, Cardio Diagnostic Is Using It In Quest to Help Prevent Cardiovascular Disease

Screenshot 2024-04-11 at 5.31.26 PM

Cardio Diagnostics Inks Groundbreaking Telehealth Agreement With Navierre And Expands Access To Cardiovascular Tests

Comments

Cardio Diagnostics Hldgs

空売り

Cardio Diagnostics Hldgs (NASDAQ:CDIO) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル